AnalysismoderateQ19-partner-outcome

Enumeration for the partner-outcome beat: what was searched, what was used, what was rejected, what could not be read

also called Q19 partner-outcome enumeration · partner-stratified outcome search record

This is the record of the search itself: which questions were typed into PubMed, how many papers came back, which ones were used, which ones were deliberately set aside and why, and which ones could not be opened at all.

The same thing, for a scientist

Search record for the question does clinical outcome in KMT2A-rearranged leukaemia differ by 3-prime fusion partner, run on 2026-09-19. Nine cohort datasets were located and written up: five reporting a partner effect (childhood AML n=1,130 and n=756, non-infant childhood ALL n=629, adult AML n=181 and n=125, single-centre paediatric AML n=150) and five reporting none (infant ALL n=115 and n=175, adult AML n=172 and n=205, post-transplant registry n=426 KMT2A-r). One cross-age B-ALL study (n=465) reports an adjusted partner effect on MRD clearance rather than survival. Five counted queries established that no menin-inhibitor trial reports response by 3-prime partner in the primary literature. Three papers were located, judged on-beat by title, and set aside for stated reasons; two protocol reports could not be read beyond their abstracts after the full PMC route failed. One premise in the dispatching brief could not be verified and is recorded as such.

Go deeper

Queries run, with counts

All PubMed, 2026-09-19. Multi-word [tiab] terms were run in singular and plural per the standing rule; karyotype terms were run in both parenthesised and bare-token form.

Query	Count	Used
`(KMT2A[tiab] OR MLL[tiab]) AND ("fusion partner"[tiab] OR "fusion partners"[tiab] OR "translocation partner"[tiab] OR "translocation partners"[tiab]) AND (prognosis OR prognostic OR outcome OR outcomes OR survival)[tiab]`	115	9 cohorts
`infant[tiab] AND (leukemia OR leukaemia)[tiab] AND (KMT2A OR MLL)[tiab] AND ("translocation partner(s)" OR "fusion partner(s)")[tiab]`	50	2
`11q23 MLL rearranged AML translocation partner prognostic outcome children`	4	2
`KMT2A rearranged acute leukemia fusion partner survival adults`	19	5
menin-inhibitor partner queries A-E (see `absence-partner-stratified-response-in-menin-inhibitor-trials`)	9, 8, 2, 2, 3	0
`Interfant-06 infant ALL outcome Pieters`	10	2
`10.1016/S0140-6736(02)08782-2[doi]` (to resolve a reference, never from recall)	1	1

One methodological note worth carrying forward: the parenthesised ("t(4;11)"[tiab]) and bare-token (t 4 11[tiab]) karyotype queries returned identical hit sets here, so the PubMed parenthesis trap did not bite in this beat. That is not a reason to stop running both.

Bounded rejections: on-beat by title, not used, with reasons

PMID 37969120 (Mrózek, Transl Pediatr 2023), Prognostic importance of the fusion partners and measurable residual disease in patients with AML who harbor 11q23/KMT2A alterations. The title is the most on-beat in the whole search. It is an editorial commentary on the I-BFM study and carries no abstract and no primary data. Used as a pointer, not cited for any claim. Would change my mind: nothing, unless it contains an original reanalysis behind the paywall.
PMID 38026790 (HemaSphere 2023), Integration of Transcriptomic Features to Improve Prognosis Prediction of Pediatric AML With KMT2A Rearrangement, n=351. Builds a 7-gene transcriptomic score that the authors position as a refinement of a stratification already based on treatment response and translocation partner. It does not report outcome by partner, so it cannot answer this beat's question - but it is the strongest evidence that the field considers the partner-based stratification improvable. Would change my mind: per-partner outcome in its supplement.
PMID 36042201 (Isobe, Nat Commun 2022), Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant ALL. Squarely relevant to the maturity and RAS confounds that this beat identifies, and cited by the cross-age B-ALL study for exactly that. Set aside because its subgrouping is by transcriptional state and RAS burden, not by 3-prime partner. Would change my mind: a partner-by-subgroup table.
PMID 29384595 (Eur J Haematol 2018), n=20 MLL-rearranged AML, reporting that MLLT1 and MLLT3 partners benefit more from allo-HSCT. Used only as counter-evidence; twenty patients across many partners cannot support a primary entry, and its direction for MLLT1 contradicts the 1,130-patient classification.
PMID 42161656 (Zhonghua Xue Ye Xue Za Zhi 2026) and PMID 41918382 (Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2026), both Chinese-language reports on adult KMT2A AML and on non-AFF1 11q23 variants (n=10) respectively. Not read; recorded so a future cycle knows they exist and were not assessed rather than not found.
PMID 30280786 (Eur Rev Med Pharmacol Sci 2018), CCLG-ALL2008 MLL-rearranged paediatric ALL. Corrected 2026-09-20: the abstract WAS retrievable and so is the full text. Europe PMC carries the abstract, and resolving the DOI returns 12,787 characters (route 5, ana-the-route-5-sweep-and-the-publisher-fingerprints). The venue caution stands and is joined by a sharper one: the KMT2A arm is 28 patients inside a 634-patient cohort, in a high-risk group of 217 split three ways, so it cannot carry a partner-stratified conclusion. Recorded as read-and-weighted-lightly rather than not-read.

A general rejection class: reviews. 39887730, 39201709, 39428967, 36979800, 42122138 and roughly a dozen others are review articles on KMT2A-rearranged leukaemia or menin inhibitors. All were title-checked, none cited, per the standing preference for primary sources.

Bounded unreadables: located, on topic, could not be read

Both were checked by the full route the standing brief requires - Europe PMC search?query=EXT_ID:<PMID>&resultType=core&format=json read for the pmcid field, not for abstractText - and both returned pmcid: null, so no fullTextXML fetch was possible.

PMID	Paper	PMCID	Full text	What its title asserts
17658395	Interfant-99 primary report, Lancet 2007	none	none	a hybrid ALL/AML protocol for infants under 1 year, with a randomised late-intensification question
31283407	Interfant-06 primary report, JCO 2019	none	none	outcome of infants under 1 year on Interfant-06, an international phase III randomised study
32845001	JPLSG MLL-10, Blood 2020	none	none	a risk-stratified therapy for infants with ALL
36256911	Ponte-di-Legno non-infant KMT2A-r ALL, JCO 2023	PMC9995095	0 chars	outcomes of childhood non-infant 11q23/KMT2A-rearranged ALL in a modern therapy era
19528532	Balgobind 11q23 paediatric AML, Blood 2009	PMC2927031	0 chars	novel prognostic subgroups in childhood 11q23/MLL-rearranged AML

For the last two a PMCID exists but fullTextXML returned zero characters, so the abstract is all that was read. No content beyond each abstract is asserted anywhere in this beat for any of these five papers, and in each case the entry says so in its caveats. In particular, the AUGMENT-101 Data Supplement Table S3, which contains the per-partner response rates, is not carried in that paper's PMC record (pmc-prop-has-supplement: no) and was not read.

A premise in the dispatching brief that could not be verified

The brief stated that Interfant-99 and Interfant-06 both report outcome by partner. From the retrievable record that could not be confirmed: neither abstract contains per-partner EFS, neither full text is open access, and Interfant-06's stated prognostic factor is KMT2A rearrangement as a binary term. The claim may still be true of the papers' tables. Per the standing instruction that a brief is a starting point and not a finding, it is recorded as unverified rather than repeated. See epi-interfant-protocols-partner-stratified-outcome-not-reported.

The nine cohorts, at a glance

Cohort	n	Population	Partner effect
I-BFM childhood AML	1,130	children, AML	yes, 24 EFS points, independent of MRD
Balgobind 11q23 AML	756	children, AML	yes, 5-yr EFS 11%-92%
Ponte-di-Legno ALL	629	children >1 yr, ALL	yes, 41.7%-91.2% by partner-by-lineage
CCHE Egypt AML	150	children, IR-AML	yes, EFS 50%-17%
Adult AML (Shen)	181	adults, AML	yes, ELL only (59.8% v 39.3%)
Adult AML (risk model)	125	adults, AML	yes, MLLT3/ELL tier, PTD-modified
MD Anderson adult AML	172	adults, AML	no
HARMONY adult AML	205	adults, AML	no
CIBMTR post-HCT	426 KMT2A-r	mostly adults, post-transplant	no
CCG 1953	115	infants, ALL	no
Moscow infant BCP-ALL	175	infants, B-ALL	no (36% v 37%, P=0.9)
Cross-age B-ALL	465	1 month-89 yr, B-ALL	yes for MRD clearance, adjusted P=0.03

Facts and figures

script	manual PubMed and Europe PMC sweep; no script committed
status	run
date of search	2026-09-19
result summary	nine partner-stratified cohort datasets located (five positive, five null, one positive for MRD clearance only); zero menin-inhibitor trials reporting response by 3-prime partner
highest value open action	retrieve AUGMENT-101 Data Supplement Table S3 and the Interfant-99/06 per-partner tables via publisher access

cohorts used

bounded rejections

bounded unreadables

inputs

[
  "PubMed E-utilities esearch/esummary/efetch",
  "Europe PMC core records and fullTextXML"
]

cohorts used — the numbers behind the chart

[
  {
    "pmid": "36996387",
    "n": 1130,
    "partner_effect": true,
    "title": "Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.",
    "authors": "van Weelderen RE, Klein K, Harrison CJ, et al.",
    "venue": "J Clin Oncol",
    "year": 2023,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "19528532",
    "n": 756,
    "partner_effect": true,
    "title": "Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.",
    "authors": "Balgobind BV, Raimondi SC, Harbott J, et al.",
    "venue": "Blood",
    "year": 2009,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "36256911",
    "n": 629,
    "partner_effect": true,
    "title": "Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study.",
    "authors": "Attarbaschi A, Möricke A, Harrison CJ, et al.",
    "venue": "J Clin Oncol",
    "year": 2023,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "40965326",
    "n": 150,
    "partner_effect": true,
    "title": "Balancing benefit and burden: treatment intensification in paediatric KMT2A rearrangements acute myeloid leukaemia.",
    "authors": "Fayez H, Elsherif M, Salem S, et al.",
    "venue": "Acta Oncol",
    "year": 2025,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "41681872",
    "n": 181,
    "partner_effect": true,
    "title": "Impact of Fusion Partners and Transplantation Benefit in Intensively Treated KMT2A-Rearranged Acute Myeloid Leukemia.",
    "authors": "Shen H, Chen J, Gong X, et al.",
    "venue": "Cancers (Basel)",
    "year": 2026,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "41121446",
    "n": 125,
    "partner_effect": true,
    "title": "KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes.",
    "authors": "Chen L, Li J, Zhu Y, et al.",
    "venue": "Exp Hematol Oncol",
    "year": 2025,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "34588432",
    "n": 172,
    "partner_effect": false,
    "title": "Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.",
    "authors": "Issa GC, Zarka J, Sasaki K, et al.",
    "venue": "Blood Cancer J",
    "year": 2021,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "38965370",
    "n": 205,
    "partner_effect": false,
    "title": "Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.",
    "authors": "Hernández-Sánchez A, González T, Sobas M, et al.",
    "venue": "Leukemia",
    "year": 2024,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "34551064",
    "n": 426,
    "partner_effect": false,
    "title": "Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.",
    "authors": "Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, et al.",
    "venue": "Blood Adv",
    "year": 2022,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "16556894",
    "n": 115,
    "partner_effect": false,
    "title": "Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.",
    "authors": "Hilden JM, Dinndorf PA, Meerbaum SO, et al.",
    "venue": "Blood",
    "year": 2006,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "40000924",
    "n": 175,
    "partner_effect": false,
    "title": "Genetic Diversity in KMT2A -r and KMT2A -Wt Groups: Assessing the Prognostic Value of Markers in BCP-ALL Among Infants.",
    "authors": "Ilyasova K, Zerkalenkova E, Soldatkina O, et al.",
    "venue": "Int J Lab Hematol",
    "year": 2025,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "41743263",
    "n": 465,
    "partner_effect": "MRD clearance only",
    "title": "Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.",
    "authors": "Hartmann AM, Bastian L, Barz MJ, et al.",
    "venue": "Hemasphere",
    "year": 2026,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "38306602",
    "n": 2080,
    "partner_effect": "null for 5-prime partner within MLLT10",
    "title": "Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia.",
    "authors": "Abla O, Ries RE, Triche T Jr, et al.",
    "venue": "Blood Adv",
    "year": 2024,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  }
]

bounded rejections — the numbers behind the chart

[
  {
    "pmid": "37969120",
    "reason": "editorial commentary, no abstract, no primary data",
    "would_change_mind": "an original reanalysis in its full text",
    "title": "Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations.",
    "authors": "Mrózek K",
    "venue": "Transl Pediatr",
    "year": 2023,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "38026790",
    "reason": "transcriptomic score, reports no outcome by partner",
    "would_change_mind": "per-partner outcome in its supplement",
    "title": "Integration of Transcriptomic Features to Improve Prognosis Prediction of Pediatric Acute Myeloid Leukemia With KMT2A Rearrangement.",
    "authors": "Li J, Zong S, Wan Y, et al.",
    "venue": "Hemasphere",
    "year": 2023,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "36042201",
    "reason": "subgroups by transcriptional state and RAS burden, not by partner",
    "would_change_mind": "a partner-by-subgroup table",
    "title": "Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.",
    "authors": "Isobe T, Takagi M, Sato-Otsubo A, et al.",
    "venue": "Nat Commun",
    "year": 2022,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "29384595",
    "reason": "n=20, used only as counter-evidence",
    "would_change_mind": "replication at adequate n",
    "title": "MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.",
    "authors": "Burillo-Sanz S, Morales-Camacho RM, Caballero-Velázquez T, et al.",
    "venue": "Eur J Haematol",
    "year": 2018,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "42161656",
    "reason": "Chinese-language, not read",
    "would_change_mind": "translation or an English abstract with per-partner numbers",
    "title": "[Clinical characteristics and prognostic analysis of adult KMT2A-associated acute myeloid leukemia].",
    "authors": "Zhou XY, Wei XE, Liu Y, et al.",
    "venue": "Zhonghua Xue Ye Xue Za Zhi",
    "year": 2026,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "41918382",
    "reason": "Chinese-language, n=10, not read",
    "would_change_mind": "n/a, too small",
    "title": "[Analysis of ten cases of Acute lymphoblastic leukemia with non-KMT2A::AFF1 transcriptional variant 11q23 rearrangements].",
    "authors": "Wang Y, Fu S, Shen Y, et al.",
    "venue": "Zhonghua Yi Xue Yi Chuan Xue Za Zhi",
    "year": 2026,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "30280786",
    "reason": "venue treated with caution, abstract not retrieved",
    "would_change_mind": "retrieval and assessment",
    "title": "The therapeutic efficacy of pediatric ALL patients with MLL gene rearrangement treated with CCLG-ALL2008 protocol.",
    "authors": "Sun YN, Hu YX, Gao L, et al.",
    "venue": "Eur Rev Med Pharmacol Sci",
    "year": 2018,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  }
]

bounded unreadables — the numbers behind the chart

[
  {
    "pmid": "17658395",
    "pmcid": null,
    "fulltext_chars": 0,
    "title_asserts": "Interfant-99 hybrid protocol for infants under 1 year with ALL",
    "title": "A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.",
    "authors": "Pieters R, Schrappe M, De Lorenzo P, et al.",
    "venue": "Lancet",
    "year": 2007,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "31283407",
    "pmcid": null,
    "fulltext_chars": 0,
    "title_asserts": "outcome of infants under 1 year on Interfant-06",
    "title": "Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.",
    "authors": "Pieters R, De Lorenzo P, Ancliffe P, et al.",
    "venue": "J Clin Oncol",
    "year": 2019,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "32845001",
    "pmcid": null,
    "fulltext_chars": 0,
    "title_asserts": "risk-stratified therapy for infants with ALL, JPLSG MLL-10",
    "title": "A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.",
    "authors": "Tomizawa D, Miyamura T, Imamura T, et al.",
    "venue": "Blood",
    "year": 2020,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "36256911",
    "pmcid": "PMC9995095",
    "fulltext_chars": 0,
    "title_asserts": "outcomes of childhood non-infant 11q23/KMT2A-rearranged ALL",
    "title": "Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study.",
    "authors": "Attarbaschi A, Möricke A, Harrison CJ, et al.",
    "venue": "J Clin Oncol",
    "year": 2023,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  },
  {
    "pmid": "19528532",
    "pmcid": "PMC2927031",
    "fulltext_chars": 0,
    "title_asserts": "novel prognostic subgroups in childhood 11q23/MLL-rearranged AML",
    "title": "Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.",
    "authors": "Balgobind BV, Raimondi SC, Harbott J, et al.",
    "venue": "Blood",
    "year": 2009,
    "title_provenance": "Title/authors/venue backfilled from PubMed esummary on 2026-09-20 because this citation stored a bare PMID with no title, which made it unscoreable by verify-citations.py. BACKFILLING IS NOT VERIFICATION: it confirms the PMID resolves to a real paper, not that this is the right paper for the claim. That still requires reading."
  }
]

unverified brief premises

[
  {
    "premise": "Interfant-99 and Interfant-06 both report outcome by partner",
    "status": "unverified - no per-partner EFS in either abstract, neither full text open access"
  }
]

review articles rejected as a class

[
  "39887730",
  "39201709",
  "39428967",
  "36979800",
  "42122138"
]

How this could bite us back

This enumeration's negative claims are only as good as the phrase 'fusion partner' being present in an abstract; a study reporting per-partner outcome in a table without flagging it in its abstract is invisible to every query run here, and that is the most likely way this beat is wrong.
Five of the most important papers in the beat were read as abstracts only, so every number taken from them is a number the authors chose to put in an abstract - a selection that systematically favours significant findings over null subgroups.

Still open

The broadest query returned 115 records of which 40 were title-checked. What is in the remaining 75, and does any of them report per-partner outcome?
Are there partner-outcome reports in the non-English literature, particularly the two Chinese-language records listed above and any Japanese reports from the JPLSG series?
Do conference abstracts from ASH and EHA contain partner-stratified menin-inhibitor response data that never reached a journal? None was searched in this beat.

Every source behind this entry (4)

E1moderate confidence 3 of 5: One strong study, or several smaller consistent ones.database
The broadest counted query for this beat, KMT2A or MLL combined with fusion/translocation partner terms in singular and plural and with prognosis/outcome/survival terms, returned 115 PubMed records on 2026-09-19, from which nine cohort datasets with partner-stratified outcome were identified.
PubMed esearch, query: (KMT2A[tiab] OR MLL[tiab]) AND ("fusion partner"[tiab] OR "translocation partner"[tiab] OR "fusion partners"[tiab] OR "translocation partners"[tiab]) AND (prognosis[tiab] OR prognostic[tiab] OR outcome[tiab] OR outcomes[tiab] OR survival[tiab]) · National Center for Biotechnology Information · PubMed (NCBI E-utilities esearch) 2026
What this evidence cannot show
Only the first 40 titles of the 115 were inspected in the initial pass; the remaining 75 were not individually title-checked, so the enumeration is not exhaustive at the tail. Restricted to title/abstract fields, so a study reporting partner outcome only in tables without saying so in its abstract is invisible to this query. English-language bias in what was subsequently read. Counts on PubMed are not stable over time.
Evidence that argues against this (1)
- The standing retired-symbol rule warns that queries keyed to current gene symbols undercount by up to tenfold; this query uses the generic phrase 'fusion partner' rather than partner gene symbols, which avoids that trap but introduces the opposite one - a paper reporting per-partner outcome without using the phrase is missed entirely. Meyer C et al. 2023
E2moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
The single most on-beat title located, a 2023 Translational Pediatrics article on the prognostic importance of fusion partners and MRD in 11q23/KMT2A AML, is an editorial commentary with no abstract and no primary data, and was rejected for that reason.
Prognostic importance of the fusion partners and measurable residual disease in patients with acute myeloid leukemia who harbor 11q23/KMT2A alterations. · Mrózek K · Transl Pediatr 2023
PMID 37969120 DOI
What this evidence cannot show
The NCBI efetch record returns no AbstractText for this PMID. Its status as a commentary is inferred from the venue, the single-author byline and the absence of an abstract; the full text was not retrieved, so this classification could be wrong.
Evidence that argues against this (1)
- The study it comments on, the 1,130-patient I-BFM analysis, is cited extensively throughout this beat, so nothing is lost by rejecting the commentary unless it contains an original reanalysis. van Weelderen RE et al. 2023
E3moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
A 351-patient paediatric KMT2A-r AML transcriptomic study explicitly describes the existing risk stratification as established on treatment response and the translocation partner of KMT2A, and proposes a 7-gene score that outperformed LSC17 - evidence that the field regards partner-based stratification as real but improvable, without itself reporting outcome by partner.
Integration of Transcriptomic Features to Improve Prognosis Prediction of Pediatric Acute Myeloid Leukemia With KMT2A Rearrangement. · Li J, Zong S, et al. · Hemasphere 2023
PMID 38026790 DOI
What this evidence cannot show
Abstract only. The comparison is against LSC17 and against the authors' own clinical model, not head to head against partner-based stratification, so it does not establish that a transcriptomic score beats the partner. Derived and validated in cohorts whose overlap with the I-BFM cohort is not stated.
Evidence that argues against this (1)
- The I-BFM study found the partner risk group independent of end-of-induction MRD in multivariable analysis, so a transcriptomic score that correlates with treatment response may be capturing the same axis rather than a better one. van Weelderen RE et al. 2023
E4moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
A multi-omics study of infant ALL defining a highly refractory RAS-burdened immature subgroup is on-beat for the maturity and comutation confounds but subgroups by transcriptional state and RAS burden rather than by 3-prime partner, and was therefore set aside.
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia. · Isobe T, Takagi M, et al. · Nat Commun 2022
PMID 36042201 DOI
What this evidence cannot show
Abstract-level assessment; the paper may contain a partner-by-subgroup table not reflected in its abstract, in which case this rejection is wrong and should be revisited. **REJECTION OVERTURNED 2026-09-19.** The condition this caveat set for its own reversal was met. The full text (PMC9427775) does partition by fusion partner, and strongly: three of the five integrative clusters correspond to MLLT1 (P = 3.7e-8), MLLT3 (P = 5.6e-6) and AFF1 (P = 5.7e-6), while no survival difference was seen across partners. Written up as `epi-infant-all-molecular-subgroups-track-partner-but-not-outcome`. Surfaced by `scripts/reading-queue.py` on low claim-to-abstract overlap.
Evidence that argues against this (2)
- The cross-age B-ALL study cites this work for the developmental-maturity axis and then shows that fusion partner contributes independently of maturity (P=0.03), so the two framings are complementary rather than alternatives and a combined analysis would be more informative than either. Hartmann AM et al. 2026
- The rejection was reversible only because it named what would overturn it. An agent writing 'set aside as off-beat' with no condition attached produces a decision nobody can audit, and this project's rejection register would then be a record of conclusions rather than of reasoning. The practice is worth the extra sentence. Nature Communications 2022

Connected to

← refutesRoute 5 rescued 2 of 32, and 21 of the 30 failures returned HTTP 200 with no article - each publisher failing at a constant, recognisable length
its statement that PMID 30280786's abstract was not retrievable
supports →The clinical outcome data do not support a single KMT2A class, and they do not refute the menin interface either
the search record behind the hypothesis
supports →Bounded absence: no menin-inhibitor trial reports response rate by 3-prime fusion partner in the primary literature
the counted queries that establish the menin reporting absence
supports →Interfant-99 and Interfant-06: what they report about partners, and what they do not
records the unreadables and the unverified brief premise
related to →Papers we know exist, know matter, and cannot read
five papers registered as read-in-abstract-only after the PMC route failed
related to →How much of this graph's mechanism is somebody else's fusion? A counted answer: 54% of fusion-bearing evidence, and 0% from a dedicated human KMT2A::AFF1 experiment
the audit that dispatched this beat